The Indian government is offering a comprehensive set of incentives to promote joint ventures (JVs) in the biotechnology and pharmaceutical sectors, recognizing their strategic importance for national health security, innovation, and economic growth. Spearheaded by the Department of Biotechnology (DBT) and the Department of Pharmaceuticals, the policy framework is designed to encourage partnerships between Indian companies and global biotech firms, research institutions, and technology developers. These JVs are expected to drive the development of biosimilars, novel biologics, gene therapies, and advanced drug delivery systems, positioning India as a global innovation hub.

To facilitate such collaborations, the government offers financial incentives through schemes like the PLI scheme for pharmaceuticals, the Biotech Industry Research Assistance Council (BIRAC) grants, and startup seed funds. Joint ventures are given priority access to biotech parks, common R&D facilities, and fast-track regulatory approvals. In addition, 100% FDI is permitted under the automatic route in greenfield pharmaceutical projects and biotech research, making India an attractive destination for foreign investment. Tax benefits, including accelerated depreciation, R&D expense deductions, and GST exemptions on certain research equipment, are also available.

The policy also emphasizes technology transfer, skill development, and clinical research infrastructure within JV models. Collaborations that focus on public health needs, such as vaccine development, antimicrobial resistance, and rare diseases, are given special support. The government aims to use joint ventures as a platform to bridge scientific capabilities with commercial scalability, enhance global competitiveness, and ensure affordable access to life-saving drugs and therapies. These targeted incentives reflect India’s commitment to building a resilient and innovation-led pharmaceutical and biotech ecosystem.